The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism - PubMed (original) (raw)
The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism
Carl Björkholm et al. Eur Neuropsychopharmacol. 2017 Apr.
Abstract
Brexpiprazole (Rexulti®), a novel D2/3 receptor (R) partial agonist, was recently approved as monotherapy for schizophrenia, demonstrating effectiveness against both positive and negative symptoms, and also approved as add-on treatment to antidepressant drugs, inducing a potent antidepressant effect with a faster onset compared to an antidepressant given alone. Moreover, brexpiprazole has demonstrated pro-cognitive effects in preclinical studies. To explore whether the observed effects may be mediated via modulation of prefrontal glutamatergic transmission, we investigated the effect of brexpiprazole, alone and in combination with the SSRI escitalopram, on prefrontal glutamatergic transmission using in vitro electrophysiological intracellular recordings of deep layer pyramidal cells of the rat medial prefrontal cortex (mPFC). Nanomolar concentrations of brexpiprazole potentiated NMDAR-induced currents and electrically evoked EPSPs via activation of dopamine D1Rs, in similarity with the effect of the atypical antipsychotic drug clozapine. The effect of an ineffective concentration of brexpiprazole was significantly potentiated by the addition of escitalopram. When combined with escitalopram, brexpiprazole also potentiated AMPAR-mediated transmission, in similarity with the clinically rapid acting antidepressant drug ketamine. The effect on the AMPAR-mediated currents was also D1R dependent. In conclusion, our data propose that brexpiprazole exerts a clozapine-like potentiation of NMDAR-mediated currents in the mPFC, which can explain its efficacy on negative symptoms of schizophrenia and the pro-cognitive effects observed preclinically. Moreover, add-on brexpiprazole to escitalopram also potentiated AMPAR-mediated transmission, which may provide a neurobiological explanation to the faster antidepressant effect of add-on brexpiprazole in major depression.
Keywords: AMPA; Antidepressant; Antipsychotic; Dopamine D1 receptor; NMDA; mPFC.
Copyright © 2017 Elsevier B.V. and ECNP. All rights reserved.
Similar articles
- Adjunctive treatment with asenapine augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic neurotransmission in the medial prefrontal cortex of the rat.
Björkholm C, Frånberg O, Malmerfelt A, Marcus MM, Konradsson-Geuken Å, Schilström B, Jardemark K, Svensson TH. Björkholm C, et al. Int J Neuropsychopharmacol. 2014 Oct 31;18(3):pyu068. doi: 10.1093/ijnp/pyu068. Int J Neuropsychopharmacol. 2014. PMID: 25522408 Free PMC article. - Interaction of dopamine D1 and NMDA receptors mediates acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex.
Chen L, Yang CR. Chen L, et al. J Neurophysiol. 2002 May;87(5):2324-36. doi: 10.1152/jn.2002.87.5.2324. J Neurophysiol. 2002. PMID: 11976371 - Ketamine-like effects of a combination of olanzapine and fluoxetine on AMPA and NMDA receptor-mediated transmission in the medial prefrontal cortex of the rat.
Björkholm C, Jardemark K, Schilström B, Svensson TH. Björkholm C, et al. Eur Neuropsychopharmacol. 2015 Oct;25(10):1842-7. doi: 10.1016/j.euroneuro.2015.07.002. Epub 2015 Jul 20. Eur Neuropsychopharmacol. 2015. PMID: 26233606 - Brexpiprazole: a new leaf on the partial dopamine agonist branch.
Hope J, Castle D, Keks NA. Hope J, et al. Australas Psychiatry. 2018 Feb;26(1):92-94. doi: 10.1177/1039856217732473. Epub 2017 Oct 10. Australas Psychiatry. 2018. PMID: 29017334 Review. - Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex.
López-Gil X, Artigas F, Adell A. López-Gil X, et al. Curr Pharm Des. 2010;16(5):502-15. doi: 10.2174/138161210790361416. Curr Pharm Des. 2010. PMID: 19909228 Review.
Cited by
- Specific Activation of Dopamine Receptor D1 Expressing Neurons in the PrL Alleviates CSDS-Induced Anxiety-Like Behavior Comorbidity with Postoperative Hyperalgesia in Male Mice.
Wang W, Liu W, Liu S, Duan D, Ma Y, Zhang Z, Li C, Tang Y, Wang Z, Xing Y. Wang W, et al. Mol Neurobiol. 2024 Aug 23. doi: 10.1007/s12035-024-04444-6. Online ahead of print. Mol Neurobiol. 2024. PMID: 39177734 - Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics.
Kojic M, Saelens J, Kadriu B, Zarate CA Jr, Kraus C. Kojic M, et al. Curr Top Behav Neurosci. 2022;56:141-167. doi: 10.1007/7854_2022_313. Curr Top Behav Neurosci. 2022. PMID: 35312993 Free PMC article. - Dopamine, Cognitive Impairments and Second-Generation Antipsychotics: From Mechanistic Advances to More Personalized Treatments.
Torrisi SA, Laudani S, Contarini G, De Luca A, Geraci F, Managò F, Papaleo F, Salomone S, Drago F, Leggio GM. Torrisi SA, et al. Pharmaceuticals (Basel). 2020 Nov 5;13(11):365. doi: 10.3390/ph13110365. Pharmaceuticals (Basel). 2020. PMID: 33167370 Free PMC article. Review. - Selective serotonin reuptake inhibitor escitalopram inhibits 5-HT3 receptor currents in NCB-20 cells.
Park YS, Sung KW. Park YS, et al. Korean J Physiol Pharmacol. 2019 Nov;23(6):509-517. doi: 10.4196/kjpp.2019.23.6.509. Epub 2019 Oct 24. Korean J Physiol Pharmacol. 2019. PMID: 31680773 Free PMC article. - A medial prefrontal cortex cell type necessary and sufficient for a rapid antidepressant response.
Hare BD, Duman RS. Hare BD, et al. Chronic Stress (Thousand Oaks). 2019 Jan-Dec;3:2470547019841358. doi: 10.1177/2470547019841358. Epub 2019 Apr 15. Chronic Stress (Thousand Oaks). 2019. PMID: 31119200 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources